GENELUX Corp Chief Technical Officer sells small share block to cover taxes. Joseph Cappello reported an open-market sale of 906 shares of GENELUX common stock at $2.42 per share on March 24, 2026. According to the disclosure, the shares were sold to cover estimated taxes related to the vesting of restricted stock units. Following this transaction, Cappello directly holds 155,154 shares of GENELUX common stock.
GENELUX Corp senior vice president sells small block of shares for taxes. SVP of Clinical Development Yu Yong sold 906 shares of common stock at $2.42 per share in an open-market transaction to cover estimated taxes from vesting restricted stock units. After this sale, Yu Yong directly holds 144,938 shares.
GENELUX Corp President and CEO Thomas Zindrick reported an open-market sale of 3,582 shares of Common Stock on March 24, 2026 at an average price of $2.42 per share. According to the footnote, the sale was made to cover estimated taxes related to vesting restricted stock units, and he now directly holds 534,849 shares.
Genelux has filed a prospectus supplement to sell up to $100,000,000 of its common stock through an "at-the-market" program with TD Securities (USA) LLC (TD Cowen) as sales agent. Shares may be sold from time to time on Nasdaq or other trading venues at market prices; TD Cowen may be paid commissions of up to 3.0% of gross proceeds.
The supplement states assumed illustrative math based on a $2.59 per‑share price, showing up to 76,749,183 shares outstanding after sales (based on 38,139,144 shares outstanding as of December 31, 2025). Net proceeds are for general corporate purposes, including research, development, clinical trials, capital expenditures and working capital.
Genelux Corporation entered into a Sales Agreement with TD Securities (USA) LLC that allows it to sell up to $100,000,000 of common stock through an at-the-market offering program. Shares will be issued from an existing shelf registration and sold on Nasdaq or in other permitted transactions.
Genelux can choose when and whether to sell, and either party may terminate the arrangement by written notice. TD Securities (TD Cowen) will receive up to 3.0% of gross proceeds and certain expenses, while net proceeds are earmarked for general corporate purposes, including research, clinical trials, capital spending, and working capital.
Genelux reported 2025 financial results and clinical updates for its lead candidate, Olvi-Vec. Revenue was $8,000, net loss was $32.145 million versus $29.869 million in 2024, and operating cash use was $25.268 million versus $21.228 million.
As of December 31, 2025, cash, cash equivalents, restricted cash and marketable securities totaled $14.6 million. Genelux received $18.5 million in subsequent net proceeds on January 8, 2026, for a stated pro forma balance of $33.1 million. The company said its existing cash may not fund planned operating expenses and capital expenditures for the next 12 months; its auditor said these conditions raise substantial doubt about the company’s ability to continue as a going concern.
Preliminary dose-escalation data with a December 31, 2025 cutoff showed a 60% disease control response (3 of 5 evaluable patients) in the VIRO-25 trial. SCLC trial data with a December 23, 2025 cutoff showed a 33% overall response rate (3 of 9). Genelux anticipates reporting topline results from its Phase 3 ovarian cancer trial in the second half of 2026.
GENELUX Corp director Thomas John reported an open-market sale of 10,000 shares of common stock. The transaction occurred on March 2, 2026 at a weighted average price of $2.8957 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on June 4, 2025. Following this sale, he directly holds 482,784 shares.
Aladar Szalay filed an amended Schedule 13G reporting beneficial ownership of 3,134,286 shares of Genelux Corp common stock, representing 8.2% of the company. This percentage is based on 38,051,771 shares outstanding as of October 30, 2025, as disclosed in Genelux’s Form 10-Q.
The filing shows 1,149,821 shares with sole voting and dispositive power, mainly through two Szalay family trusts, and 1,984,465 shares with shared voting and dispositive power, held by the Szalay Trust dated August 30, 2021 and the reporting person’s spouse. The event date triggering the filing is December 31, 2025.
Genelux Corporation filed a current report outlining an update to its corporate presentation with new business and strategic information. The refreshed presentation, dated February 2026, may be used by management in future meetings and is available in the Investors section of the company’s website.
The presentation is furnished as Exhibit 99.1 under a Regulation FD disclosure and is not deemed filed for liability purposes under the Exchange Act or incorporated into other securities filings unless specifically referenced.